Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus radiotherapy for newly diagnosed pediatric malignant brainstem glioma
ChiCTR2300077363Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in brainstem glioma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival at 6 months. Started Nov 2023; status: recruiting.
02
Drugs
anlotinib
03
Conditions
brainstem glioma
Beyond the preview
Go deeper on ChiCTR2300077363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077363.